Aurinia Pharmaceuticals Management
Management criteria checks 1/4
Aurinia Pharmaceuticals' CEO is Peter Greenleaf, appointed in Apr 2019, has a tenure of 5.58 years. total yearly compensation is $10.57M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth €2.62M. The average tenure of the management team and the board of directors is 4.5 years and 1.3 years respectively.
Key information
Peter Greenleaf
Chief executive officer
US$10.6m
Total compensation
| CEO salary percentage | 7.8% |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.2% |
| Management average tenure | 4.5yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$23m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$11m | US$823k | -US$78m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$9m | US$791k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$1m | US$724k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$148m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$11m | US$673k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$110m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$5m | US$438k | -US$88m |
Compensation vs Market: Peter's total compensation ($USD10.57M) is above average for companies of similar size in the German market ($USD1.64M).
Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.
CEO
Peter Greenleaf (54 yo)
5.6yrs
Tenure
US$10,573,359
Compensation
Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been Chief Executive Officer and Director of Aurinia Pharmaceuticals...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$10.57m | 0.22% € 2.6m | |
| Chief Financial Officer | 4.6yrs | US$3.98m | 0.078% € 939.8k | |
| Chief Operations Officer | no data | US$4.56m | 0.11% € 1.3m | |
| Executive Vice President of General Counsel | 4yrs | US$3.60m | 0.055% € 656.7k | |
| Head of the Corporate Communications & Investor Relations | no data | no data | no data | |
| Chief Business Officer | 4.4yrs | US$702.00k | no data | |
| Senior Vice President of Global Regulatory Affairs | no data | no data | no data | |
| Chief Medical Officer | no data | no data | 0.078% € 934.0k | |
| Senior Vice President of Manufacturing & Supply Chain | no data | no data | no data | |
| Vice President of Investor Relation | no data | no data | no data |
4.5yrs
Average Tenure
53yo
Average Age
Experienced Management: IKAP's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$10.57m | 0.22% € 2.6m | |
| Chairman | less than a year | no data | no data | |
| Independent Director | 5yrs | US$267.28k | 0.010% € 123.4k | |
| Director | no data | no data | no data | |
| Independent Director | 1.3yrs | US$361.51k | 0.0093% € 112.0k | |
| Independent Director | 1.3yrs | US$359.41k | 0.0089% € 106.2k | |
| Independent Non-Executive Director | 9.5yrs | US$249.92k | 0.031% € 371.7k |
1.3yrs
Average Tenure
62yo
Average Age
Experienced Board: IKAP's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.